BridgeBio Pharma Posts Narrower Q3 Loss, Revenue Tops Estimates; BBIO Shares Up 6%

BridgeBio Pharma Inc. (BBIO) on Thursday reported a third-quarter loss of $56.7 million, or 42 cents per share, beating Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 60 cents per share. The Palo Alto, California-based rare disease drug developer posted revenue of $353.2 million for the period, also topping forecasts; six analysts surveyed by Zacks expected $296.6 million. BridgeBio shares have declined 7.5% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $70.78, a climb of 6% over the last 12 months.